Literature DB >> 10454440

Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells. Potential role of p53 in regulation of vascular smooth muscle cell growth.

M Aoki1, R Morishita, H Matsushita, S Hayashi, H Nakagami, K Yamamoto, A Moriguchi, Y Kaneda, J Higaki, T Ogihara.   

Abstract

Loss of activity of the p53 tumor suppressor gene product has been postulated in the pathogenesis of human restenosis. Although the antioncogenes p53 and retinoblastoma (Rb) susceptibility gene have been reported to play a pivotal role in cell cycle progression in various cells, the role of p53 and Rb in the growth of human vascular smooth muscle cells (VSMC) has not yet been clarified. We used antisense strategy against p53 and Rb genes by the viral envelope-liposomal method. Transfection of antisense p53 oligodeoxynucleotides (ODN) alone resulted in an increase in DNA synthesis compared with control (P<0.01). Similarly, transfection of antisense Rb ODN alone resulted in a higher DNA synthesis rate than control (P<0.01). Moreover, increase in VSMC number was only induced by transfection of antisense p53 ODN alone or cotransfection of p53/Rb ODN (P<0.01), whereas a single transfection of antisense Rb ODN had little effect on cell number. Therefore, we hypothesized that this discrepancy is due to the induction of apoptosis mediated by p53. Interestingly, apoptotic cells were markedly increased in VSMC transfected with antisense Rb ODN alone, accompanied by the induction of p53 protein. The number of apoptotic cells was attenuated by cotransfection of antisense p53 ODN (P<0.01). We finally examined the molecular mechanisms of apoptosis induced by the absence of Rb. In VSMC transfected with antisense Rb ODN, bax, a promoter of apoptosis, was significantly increased in VSMC transfected with antisense Rb ODN (P<0.01), whereas bcl-2 and Fas did not play a pivotal role in the induction of apoptosis. Overall, these data first demonstrated that the antioncogenes p53 and Rb negatively regulated the cell cycle in VSMC, suggesting that the modulation of their activity may mediate VSMC growth such as that in restenosis and atherosclerosis. The presence of p53 plays a pivotal role in the regulation of apoptosis in human VSMC growth, probably through the bax pathway. These results provide evidence that p53 is a functional link between cell growth and apoptosis in VSMC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454440     DOI: 10.1161/01.hyp.34.2.192

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.

Authors:  Shunji Shiohira; Takumi Yoshida; Hidekazu Sugiura; Satsuki Yoshida; Michihiro Mitobe; Katsunori Shimada; Takashi Ohba; Ken Tsuchiya; Takashi Kabaya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-07-20       Impact factor: 2.801

2.  Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival.

Authors:  David J Nagel; Toru Aizawa; Kye-Im Jeon; Weimin Liu; Amy Mohan; Heng Wei; Joseph M Miano; Vincent A Florio; Pingjin Gao; Vyacheslav A Korshunov; Bradford C Berk; Chen Yan
Journal:  Circ Res       Date:  2006-03-02       Impact factor: 17.367

3.  TP53 haplotype-based analysis and incidence of post-angioplasty restenosis.

Authors:  Robert Y L Zee; Nancy R Cook; Chung-Ah Kim; Arturo Fernandez-Cruz; Klaus Lindpaintner
Journal:  Hum Genet       Date:  2004-01-22       Impact factor: 4.132

4.  S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy.

Authors:  Steven Greenway; Robert Jan van Suylen; Gideon Du Marchie Sarvaas; Edwin Kwan; Noona Ambartsumian; Eugene Lukanidin; Marlene Rabinovitch
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

5.  Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.

Authors:  Hideki Ishii; Yoshitake Kumada; Takanobu Toriyama; Toru Aoyama; Hiroshi Takahashi; Shigeki Yamada; Yoshinari Yasuda; Yukio Yuzawa; Shoichi Maruyama; Seiichi Matsuo; Tatsuaki Matsubara; Toyoaki Murohara
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 8.237

6.  Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease.

Authors:  Wiwat Chancharoenthana; Asada Leelahavanichkul; Sujittra Taratummarat; Jutamas Wongphom; Khajohn Tiranathanagul; Somchai Eiam-Ong
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

Review 7.  Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?

Authors:  George Galyfos; Argyri Sianou
Journal:  Vasc Specialist Int       Date:  2017-09-30

8.  p53 codon 72 polymorphism and coronary artery disease: evidence of interaction with ACP₁.

Authors:  Fulvia Gloria-Bottini; Maria Banci; Patrizia Saccucci; Anna Neri; Egidio Bottini; Andrea Magrini
Journal:  Med Sci Monit       Date:  2012-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.